Business
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated feder
About this update from Gh Research Plc
[{"type":"image","alt":"GH Research PLC","displaySize":"","headline":null,"caption":"GH Research PLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/bbe2ccbcef97364f95786cf35b67e784"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TzYeYcZw0Wd4_NH40nFSLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/bbe2ccbcef97364f95786cf35b67e784","width":300,"height":94}},"lazy":false},{"type":"text","content":"DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness. GH Research continues to advance GH001, its proprietary inhaled mebufotenin product candidate, toward initiation of a global pivotal Phase 3 program in treatment-resistant depression (TRD) in 2026.","length":820,"tagName":"p"},{"type":"text","content":"“We commend the Administration for recognizing the magnitude of the mental health crisis and the urgent need for innovative, evidence-based therapies for patients with serious mental illness. The Executive Order’s emphasis on scientific rigor and cross-agency coordination is well aligned with the approach required to deliver practice-changing treatments, and we remain focused on advancing GH001 toward a global pivotal Phase 3 program,” said Dr. Velichka Valcheva, Chief Executive Officer of GH Research.","length":507,"tagName":"p"},{"type":"text","content":"About GH Research PLC","length":21,"tagName":"p"},{"type":"text","content":"GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.","length":305,"tagName":"p"},{"type":...